Association between Sleep Duration and Measurable Cardiometabolic Risk Factors in Healthy Korean Women: The Fourth and Fifth Korean National Health and Nutrition Examination Surveys (KNHANES IV and V)
Table 2
Prevalence (%) and odds ratio (95% confidence interval) for the components of metabolic syndrome according to sleep duration.
Sleep duration (hours a day)
5
6
7
8
9
-trend
Reduced HDL
Prevalence (%)
571 (51.5)
956 (46.7)
1288 (49.6)
1036 (49.8)
331 (49.4)
Unadjusted
0.08 (0.94–1.24)
0.89 (0.79–1.00)
Reference
1.00 (0.90–1.13)
0.99 (0.84–1.18)
0.79
Model 1
0.84 (0.73–0.98)
0.86 (0.76–0.96)
Reference
1.03 (0.92–1.16)
1.03 (0.87–1.23)
<0.01
Model 2
0.84 (0.71–1.00)
0.88 (0.77–1.00)
Reference
1.04 (0.91–1.18)
1.07 (0.89–1.30)
<0.01
Model 3
0.82 (0.69–0.97)
0.86 (0.75–0.98)
Reference
1.05 (0.92–1.20)
1.13 (0.93–1.38)
<0.01
High triglycerides
Prevalence (%)
238 (21.5)
292 (14.3)
388 (14.9)
307 (14.8)
120 (17.9)
Unadjusted
1.56 (1.30–1.86)
0.95 (0.80–1.12)
Reference
0.98 (0.84–1.16)
1.24 (0.99–1.56)
0.02
Model 1
1.03 (0.85–1.25)
0.89 (0.75–1.05)
Reference
1.04 (0.88–1.23)
1.35 (1.06–1.71)
0.04
Model 2
0.89 (0.72–1.11)
0.86 (0.75–1.00)
Reference
reference
1.38 (1.08–1.76)
<0.01
Model 3
0.87 (0.70–1.09)
0.81 (0.49–0.99)
Reference
0.99 (0.82–1.20)
1.48 (1.13–1.93)
<0.01
Elevated WC
Prevalence (%)
515 (46.5)
744 (36.3)
856 (33.0)
658 (31.6)
193 (28.8)
Unadjusted
1.77 (0.53–2.04)
1.16 (1.03–1.31)
Reference
0.94 (0.83–1.06)
1.82 (0.89–0.99)
<0.01
Model 1
1.17 (1.00–1.36)
1.07 (0.96–1.24)
Reference
0.99 (0.87–1.12)
0.89 (0.72–1.06)
<0.01
Model 2
1.22 (1.03–1.45)
1.09 (0.95–1.25)
Reference
0.96 (0.84–1.11)
0.81 (0.65–1.01)
<0.01
Model 3
1.24 (0.97–1.58)
1.08 (0.88–1.32)
Reference
1.09 (0.89–1.34)
0.93 (0.67–1.29)
0.21
Impaired fasting glucose
Prevalence (%)
186 (16.8)
306 (14.9)
355 (16.7)
294 (14.1)
86 (12.8)
Unadjusted
0.27 (1.05–1.55)
1.11 (0.94–1.31)
Reference
1.04 (0.88–1.23)
0.93 (0.72–1.20)
0.02
Model 1
0.86 (0.70–1.05)
1.05 (0.89–1.24)
Reference
1.10 (0.83–1.30)
1.03 (0.79–1.33)
0.10
Model 2
0.92 (0.73–1.15)
1.07 (0.94–1.37)
Reference
1.14 (0.94–1.37)
1.12 (0.85–1.49)
0.14
Model 3
0.90 (0.72–1.14)
1.06 (0.87–1.28)
Reference
1.15 (0.95–1.39)
1.18 (0.88–1.57)
0.06
High blood pressure
Prevalence (%)
228 (20.6)
275 (13.4)
337 (13.0)
247 (11.9)
82 (12.2)
Unadjusted
1.74 (1.44–2.09)
1.04 (0.88–1.24)
Reference
0.90 (0.76–1.08)
0.94 (0.72–1.21)
<0.01
Model 1
0.90 (0.74–1.11)
0.74 (0.79–1.13)
Reference
0.98 (0.81–1.18)
1.05 (0.79–1.39)
0.27
Model 2
0.91 (0.72–1.14)
0.91 (0.75–1.11)
Reference
0.97 (0.79–1.19)
1.06 (0.78–1.43)
0.29
Model 3
0.90 (0.72–1.14)
0.90 (0.73–1.10)
Reference
0.97 (0.79–1.20)
1.09 (0.80–1.49)
0.20
Data of prevalence category are numbers and percentages. The metabolic syndrome was defined using the National Cholesterol Education Program-Adult Treatment Panel III criteria. Model 1, adjusted for age, education, and monthly income. Model 2, adjusted for smoking and alcohol status, physical activity, and energy intake plus Model 1. Model 3, adjusted for body mass index plus Model 2. value < 0.05, value < 0.1.
